

Heart Care*



Personalized Heart Care

All Trials Inventory

| Study / Acronym | Full Official Study Title |
|--------------------------------|--|
| ASSENT 1 | |
| GUSTO-3 | |
| TIMI 11B (ESSENCE) | |
| IMPRESS (CHF Omapratilat) | |
| INTIME -2 | |
| moxcon | |
| sb endothelin | |
| valiant | |
| 2nd symphony | |
| BRAVO (Lotrafiban) | |
| ephesus | |
| InTime -2B | |
| PENTA- Knee (Pentasaccharide) | |
| PENTA-2 (Pentasaccharide) | |
| CURE | |
| MATISSE DVT | |
| NICE-3 (Co Investigator) | |
| TIMI ER 19 | |
| AF-CHF Study | |
| MATISSE PE | |
| PROVE IT (TIMI) | |
| ONTARGET / TRANSCEND | Effectiveness and Safety of Ramipril Alone or in Combination With Telmisartan in People at High Vascular Risk for TRANSCEND and ONTARGET |
| TIMI 25 EXTRACT | |
| TIMI AVANT GARDE | |
| AVERROES A Fib | A Phase III Study of Apixaban in Patients With Atrial Fibrillation (AVERROES) |
| ACCLAIM | |
| ACTIVE | |

| | |
|--------------------------|---|
| ADONIS (Atrial Fib) | |
| Amgen | |
| ARISE | |
| Aristotle | Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation |
| ARISTOTLE Afib | Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation |
| ASSENT 3 | |
| ATHENA Afib | A Trial With Dronedaron to Prevent Hospitalization or Death in Patients With Atrial Fibrillation |
| Atlas | |
| Avant Gard | |
| Cassiopea | |
| CASSIOPEA Pul embolism | |
| CHARISMA | |
| CLARITY (STEMI) | |
| CTAF | |
| ELIXA | Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) |
| ENGAGE TIMI | Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation |
| Fact | |
| FOCUS | |
| Focus | |
| GAP | |
| HAT (Home AED Trial) | |
| IMPROVE IT TIMI | Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (IMPROVE-IT) |
| JUPITER | JUPITER - Crestor 20 mg versus Placebo in Prevention of Cardiovascular (CV) Events |
| MAIA | |
| MERLIN | |
| MIRACL | |
| OASIS 5 | |
| OPUS/TIMI 16 (Orbofiban) | |
| Organon | |
| ORIGIN | The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention) |

| | |
|-------------------------------------|---|
| PEGASUS TIMI 54 | Prevention of Cardiovascular Events (e.g., Heart Attack or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin |
| PLATO | A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome |
| PRIME DHF (Diastolic Heart Failure) | |
| REDEEEM | |
| ROCKET (Roxifiban) | An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System (CNS) Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation |
| SAVOR TIMI 48 | Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications |
| SOLID TIMI 52 | The Stabilization Of pLaques using Darapladib - Thrombolysis In Myocardial Infarction 52 Trial |
| STABILITY | The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial |
| TRA 2 P TIMI 50 | Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis |
| Transfer AMI | |
| Vasogen | |
| WAVE | |
| Wave | |
| ISIS 2 | |